231 related articles for article (PubMed ID: 11016597)
1. Antibodies to the major linear neutralizing domains of cytomegalovirus glycoprotein B among natural seropositives and CMV subunit vaccine recipients.
Marshall GS; Li M; Stout GG; Louthan MV; Duliège AM; Burke RL; Hunt LA
Viral Immunol; 2000; 13(3):329-41. PubMed ID: 11016597
[TBL] [Abstract][Full Text] [Related]
2. Detection of cytomegalovirus infection during clinical trials of glycoprotein B vaccine.
Zhang C; Pass RF
Vaccine; 2004 Dec; 23(4):507-10. PubMed ID: 15530699
[TBL] [Abstract][Full Text] [Related]
3. Protection against congenital cytomegalovirus infection and disease in guinea pigs, conferred by a purified recombinant glycoprotein B vaccine.
Schleiss MR; Bourne N; Stroup G; Bravo FJ; Jensen NJ; Bernstein DI
J Infect Dis; 2004 Apr; 189(8):1374-81. PubMed ID: 15073673
[TBL] [Abstract][Full Text] [Related]
4. Comparison of monovalent glycoprotein B with bivalent gB/pp65 (GP83) vaccine for congenital cytomegalovirus infection in a guinea pig model: Inclusion of GP83 reduces gB antibody response but both vaccine approaches provide equivalent protection against pup mortality.
Swanson EC; Gillis P; Hernandez-Alvarado N; Fernández-Alarcón C; Schmit M; Zabeli JC; Wussow F; Diamond DJ; Schleiss MR
Vaccine; 2015 Jul; 33(32):4013-8. PubMed ID: 26079615
[TBL] [Abstract][Full Text] [Related]
5. HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions.
Nelson CS; Huffman T; Jenks JA; Cisneros de la Rosa E; Xie G; Vandergrift N; Pass RF; Pollara J; Permar SR
Proc Natl Acad Sci U S A; 2018 Jun; 115(24):6267-6272. PubMed ID: 29712861
[TBL] [Abstract][Full Text] [Related]
6. Antibodies to recombinant-derived glycoprotein B after natural human cytomegalovirus infection correlate with neutralizing activity.
Marshall GS; Rabalais GP; Stout GG; Waldeyer SL
J Infect Dis; 1992 Feb; 165(2):381-4. PubMed ID: 1309850
[TBL] [Abstract][Full Text] [Related]
7. Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccine Elicits Antibody Responses with Greater Durability and Breadth than MF59-Adjuvanted gB Protein Immunization.
Nelson CS; Jenks JA; Pardi N; Goodwin M; Roark H; Edwards W; McLellan JS; Pollara J; Weissman D; Permar SR
J Virol; 2020 Apr; 94(9):. PubMed ID: 32051265
[TBL] [Abstract][Full Text] [Related]
8. Enveloped virus-like particle expression of human cytomegalovirus glycoprotein B antigen induces antibodies with potent and broad neutralizing activity.
Kirchmeier M; Fluckiger AC; Soare C; Bozic J; Ontsouka B; Ahmed T; Diress A; Pereira L; Schödel F; Plotkin S; Dalba C; Klatzmann D; Anderson DE
Clin Vaccine Immunol; 2014 Feb; 21(2):174-80. PubMed ID: 24334684
[TBL] [Abstract][Full Text] [Related]
9. Location, location, timing: analysis of cytomegalovirus epitopes for neutralizing antibodies.
Schrader JW; McLean GR
Immunol Lett; 2007 Sep; 112(1):58-60. PubMed ID: 17714794
[TBL] [Abstract][Full Text] [Related]
10. Vaccination of seropositive subjects with CHIRON CMV gB subunit vaccine combined with MF59 adjuvant for production of CMV immune globulin.
Drulak MW; Malinoski FJ; Fuller SA; Stewart SS; Hoskin S; Duliege AM; Sekulovich R; Burke R; Winston S
Viral Immunol; 2000; 13(1):49-56. PubMed ID: 10733168
[TBL] [Abstract][Full Text] [Related]
11. Enzyme-linked immunosorbent assay for measurement of cytomegalovirus glycoprotein B antibody in serum.
Hackett DJ; Zhang C; Stefanescu C; Pass RF
Clin Vaccine Immunol; 2010 May; 17(5):836-9. PubMed ID: 20219875
[TBL] [Abstract][Full Text] [Related]
12. Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults.
Bernstein DI; Schleiss MR; Berencsi K; Gonczol E; Dickey M; Khoury P; Cadoz M; Meric C; Zahradnik J; Duliege AM; Plotkin S
J Infect Dis; 2002 Mar; 185(5):686-90. PubMed ID: 11865427
[TBL] [Abstract][Full Text] [Related]
13. Glycoprotein H of human cytomegalovirus is a major antigen for the neutralizing humoral immune response.
Urban M; Klein M; Britt WJ; Hassfurther E; Mach M
J Gen Virol; 1996 Jul; 77 ( Pt 7)():1537-47. PubMed ID: 8757997
[TBL] [Abstract][Full Text] [Related]
14. Lack of antibodies against the antigen domain 2 epitope of cytomegalovirus (CMV) glycoprotein B is associated with CMV disease after renal transplantation in recipients having the same glycoprotein H serotypes as their donors.
Ishibashi K; Tokumoto T; Shirakawa H; Hashimoto K; Ikuta K; Kushida N; Yanagida T; Shishido K; Aikawa K; Toma H; Inoue N; Yamaguchi O; Tanabe K; Suzutani T
Transpl Infect Dis; 2011 Jun; 13(3):318-23. PubMed ID: 20804536
[TBL] [Abstract][Full Text] [Related]
15. Antibody responses to rhesus cytomegalovirus glycoprotein B in naturally infected rhesus macaques.
Yue Y; Zhou SS; Barry PA
J Gen Virol; 2003 Dec; 84(Pt 12):3371-3379. PubMed ID: 14645918
[TBL] [Abstract][Full Text] [Related]
16. A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne).
Adler SP; Plotkin SA; Gonczol E; Cadoz M; Meric C; Wang JB; Dellamonica P; Best AM; Zahradnik J; Pincus S; Berencsi K; Cox WI; Gyulai Z
J Infect Dis; 1999 Sep; 180(3):843-6. PubMed ID: 10438376
[TBL] [Abstract][Full Text] [Related]
17. Novel trimeric human cytomegalovirus glycoprotein B elicits a high-titer neutralizing antibody response.
Cui X; Cao Z; Wang S; Lee RB; Wang X; Murata H; Adler SP; McVoy MA; Snapper CM
Vaccine; 2018 Sep; 36(37):5580-5590. PubMed ID: 30082162
[TBL] [Abstract][Full Text] [Related]
18. Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies.
Baraniak I; Kropff B; Ambrose L; McIntosh M; McLean GR; Pichon S; Atkinson C; Milne RSB; Mach M; Griffiths PD; Reeves MB
Proc Natl Acad Sci U S A; 2018 Jun; 115(24):6273-6278. PubMed ID: 29686064
[TBL] [Abstract][Full Text] [Related]
19. Preclinical evaluations of peptide-conjugate vaccines targeting the antigenic domain-2 of glycoprotein B of human cytomegalovirus.
Finnefrock AC; Freed DC; Tang A; Li F; He X; Wu C; Nahas D; Wang D; Fu TM
Hum Vaccin Immunother; 2016 Aug; 12(8):2106-2112. PubMed ID: 26986197
[TBL] [Abstract][Full Text] [Related]
20. Little role of anti-gB antibodies in neutralizing activity of patient's sera with human cytomegalovirus (HCMV) infection.
Park JW; Kim DJ; Kim J; Park CG; Hwang ES; Cha CY
J Korean Med Sci; 2000 Apr; 15(2):133-8. PubMed ID: 10803687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]